Skip to main content
OpenTrials
Completed

NCT Number: NCT03838822

Kinetics of Metabolic Cofactors in NAFLD

There is a strong correlation between major adverse health consequences of obesity and development of non-alcoholic fatty liver disease (NAFLD). NAFLD is characterized by abnormal hepatic accumulation of triglycerides and other lipids. It has become a worldwide health problem that accelerates cirrhosis, type 2 diabetes mellitus (T2DM), and especially premature cardiovascular morbidity and mortality.

The plasma level of glutathione (GSH) is typically depleted in individuals with metabolism related disorders. However, cellular GSH levels cannot be increased by supplementing GSH and it must be synthesized within the liver either de novo or by salvation pathway. The level of GSH is not enough to maintain and regulate the thiol redox status of the liver in subjects with high hepatic steatosis at fasting stage due to the depletion of glycine. Glycine can be synthesized via the interconversion of serine. It has been shown that the serine synthesis is downregulated in patients with NAFLD and supplementation of serine has attenuated alcoholic fatty liver by enhancing homocysteine metabolism in mice and rats. Depleted liver glutathione is also restored by the administration of N-acetylcystein as in acetaminophen poising. L-carnitine and nicotinamide that both stimulate the transfer of fatty acids from cytosol to mitochondria have been identified as two additional cofactors that are depleted in patients with NAFLD.

In this study, the kinetics in blood of pivotal metabolic cofactors, serine, L-carnitine, N-acetylcystein and nicotinamide after single and simultaneous dietary supplementation, are measured.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–40 year

Sex eligibility

Male

Study type

Interventional

Phase

Early Phase 1

Primary location

Hanns-Ulrich Marschall, Gothenburg, Sweden

Loading trial locations.

About this study

In 10 healthy subjects with BMI <30 kg/m2 the plasma concentrations of 4 natural compounds (nicotinamide riboside, L-carnitine, L-serine and N-acetylcystein) are measured by ultra-performance liquid chromatography-tandem mass spectrometry (UPLCMSMS) after individual and combined administration, on five consecutive days and at every hour during 9 hours after administration. The study will start at 8:00 every morning and at each time point, blood samples will be collected.

The taste and any potential sensing of the co-factors such as vertigo, nausea, bowel movement will be recorded.

Each participant will receive one oral dose of Day 1: 1 g nicotinamide riboside; Day 2: 3 g L-carnitine; Day 3: 5 g N-acetylcystein; Day 4: 20 g L-serine; Day 5: combined 1 g nicotinamide riboside, 3 g L-carnitine, 5 g N-acetylcystein, and 20 g L-serine

In addition, untargeted metabolomics analysis as well as O-link proteomics analysis we be performed to study effect of the administered cofactors.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Healthy without any medication, no smokers, no obesity

Exclusion criteria

Any known disease, obesity

Treatment and study plan

Cofactors

Dietary Supplement

Oral administration of 1g nicotinamide riboside, 3g L-carnitine, 20g serine and 5g N-acetylcystein, first as single compounds, then combined, on 5 days

Primary outcomes

  1. Changes of plasma levels of nicotinamide riboside measured by mass spectrometry

    Time frame: Twenty-four hours after administration

    Plasma levels of nicotinamide riboside by UPLCMSMS at 8 time points during 24h after administration

  2. Changes of plasma levels of L-carnitine measured by mass spectrometry

    Time frame: Twenty-four hours after administration

    Plasma levels of L-carnitine (nM) measured by UPLCMSMS at 8 time points during 24h after administration

  3. Changes of plasma levels of L-serine measured by mass spectrometry

    Time frame: Twenty-four hours after administration

    Plasma levels of L-serine (nM) measured by UPLCMSMS at 8 times points during 24h after administration

  4. Changes of plasma levels of N-acetylcystein measured by mass spectrometry

    Time frame: Twenty-four hours after administration

    Plasma levels of N-acetylcystein (nM) measured by UPLCMSMS at 8 times points during 24h after administration

Secondary outcomes

  1. Changes in the plasma level of metabolites associated with the supplementation of metabolic co-factors.

    Time frame: Twenty-four hours after administration of combined cofactors

    Untargeted metabolomic analysis using mass spectrometry. (Untargeted = not pre-specified in terms of outcome)

  2. Changes in the plasma level of inflammation-related proteins associated with the supplementation of metabolic co-factors.

    Time frame: Twenty-four hours after administration of combined cofactors

    Changes in the plasma level of inflammation related proteins associated with the supplementation of metabolic co-factors.

Sponsors and collaborators

Lead sponsor

Sahlgrenska University Hospital

Other

Collaborators

  • Chalmers University of Technology
  • Karolinska Institutet

Registry information

Official study title

Kinetics of Metabolic Cofactors After Oral Supplementation in Healthy Subjects

Acronym: NAFLDCOFCAL

Important dates

Study start
2018
Primary completion
2018
Study completion
2018
First posted
Feb 12, 2019
Registry last updated
Feb 15, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.